PACIRA BIOSCIENCES, INC. Income Tax Effects Allocated Directly to Equity, Equity Transactions
PACIRA BIOSCIENCES, INC. (PCRX) reported Income Tax Effects Allocated Directly to Equity, Equity Transactions of $20.45 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Expense Statement
us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityEquityTransactions · last filed 2021-11-03
- PACIRA BIOSCIENCES, INC. income tax effects allocated directly to equity, equity transactions for the quarter ending 2020-09-30 was $20.45M.
| Period end | Income Tax Effects Allocated Directly to Equity, Equity Transactions 3 month | Income Tax Effects Allocated Directly to Equity, Equity Transactions 9 month |
|---|---|---|
| 2020-09-30 | $20.45M 10-Q · filed 2021-11-03 | $20.45M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |